Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Depomed, Inc.
Depomed Completes Enrollment of Phase 3 Clinical Program of DM-1796 in Post-Herpetic Neuralgia
June 20th, 2009
Depomed, Inc. (NASDAQ:DEPO) announced that it has completed enrollment of the Phase 3 clinical trial of DM-1796 for the treatment of post-herpetic neuralgia. “We are glad that we successfully arrived at another milestone that brings Depomed closer to potential milestone payments related to the development of DM-1796 and further royalties and sales milestones upon its approval. We remain excited to have Solvay Pharmaceuticals as a strong and committed partner in the neuroscience field, we share with their expectation that DM-1796 could become a significant product for the treatment of neuropathic pain,” said Carl A. Pelzel, Depomed’s president and chief executive...
Source: Law & Health Weekly (2009-06-20)
|
